- Netflix: The Biggest Empty Promise Since Enron?
- Why Car Prices Vary From City To City
- Big Bank Phobia: Not Too Big to Fail
- Expect Your Health Care in Retirement to Hit $200,000
- Apple Should Still Fire Tim Cook
Article
Making The Call: Celgene's Abraxane Will Work in Pancreatic Cancer
A key question is whether Abraxane will be used more than a cheaper, four-drug chemo cocktail.
06:00AM 10/15/12
Article
Sarepta Shares Still Have Upside
Contributor Nate Sadeghi works the numbers and says Sarepta is still under-valued.
10:43AM 10/03/12
Article
Threshold's Pancreatic Cancer Drug May be Obsolete Before Launch
Improved treatments for pancreatic cancer challenge the relevance of Threshold's TH-302
07:30AM 10/01/12
Article
A New Reason to be Bullish About Sarepta Therapeutics
A longer study blind suggests eteplirsen is really helping muscular dystrophy patients.
07:00AM 09/24/12
Article
Idenix Pharma: Guilty By Association
Idenix shares are dead money due to FDA safety concerns about Idenix's lead hepatitis C drug.
07:48AM 09/21/12
Article
Bull Case on Peregrine Pharma Shouldn't Be Dismissed
Believers in Peregrine's lung cancer drug bavituximab state their case.
09:33AM 09/17/12
Article
Peregrine Pharma: Not Good Enough to Own, Too Risky to Short
Nate Sadeghi examines Peregrine's lung cancer drug bavituximab
11:53AM 09/10/12
Article
More Reasons to Invest in Sarepta With Caution
Nate Sadeghi answers critics who think he's being too hard on Sarepta and its DMD drug eteplirsen.
10:35AM 08/27/12
Article
Sarepta's Risks Shouldn't Be Ignored
There are legit reasons to like Sarepta Therapeutics but only if these red flags can be avoided.
07:00AM 08/21/12
Article
In These Turbulent Times, Reach for Merck
The company's pipeline could deliver an upside surprise, plus you get a 4% dividend while you wait.
09:03AM 08/13/12